<DOC>
	<DOC>NCT02854605</DOC>
	<brief_summary>The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in participants with nonalcoholic steatohepatitis (NASH).</brief_summary>
	<brief_title>Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Key Meets the following conditions: A clinical diagnosis of nonalcoholic fatty liver disease (NAFLD) Screening magnetic resonance imaging proton density fat fraction (MRIPDFF) with ≥ 8% steatosis Screening magnetic resonance elastography (MRE) with liver stiffness ≥ 2.5 kilopascal (kPa) OR A historical liver biopsy within 12 months of screening consistent with NASH with fibrosis, but not cirrhosis, and No documented weight loss &gt; 5% between the date of the liver biopsy and screening. Platelet count ≥ 150,000/mm^3 Albumin ≥ 3.3 g/dL Serum creatinine ≤ upper limit of normal (ULN) Key Pregnant or lactating females Alanine aminotransferase (ALT) &gt; 5x upper limit of the normal range (ULN) Other causes of liver disease including autoimmune, viral, and alcoholic liver disease Cirrhosis of the liver Prior history of decompensated liver disease, including ascites, hepatic encephalopathy, or variceal bleeding Body mass index (BMI) &lt; 18 kg/m^2 Uncontrolled diabetes mellitus (hemoglobin A1c &gt; 9% at screening) International normalized ratio (INR) &gt; 1.2 unless on anticoagulant therapy Total bilirubin &gt; 1 x ULN, except with diagnosis of Gilbert's syndrome NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-alcoholic fatty liver disease (NAFLD)</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>GS-9674</keyword>
</DOC>